Today: 9 April 2026
Subscribe
Browse Category

Biotechnology 21 November 2025 - 7 December 2025

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics (CRSP) Stock on 7 December 2025: Latest Price, News, Forecasts and Gene‑Editing Outlook

CRISPR Therapeutics closed at $56.88 on December 5, giving the company a market cap near $5.9 billion. The State Board of Administration of Florida Retirement System disclosed a new $1.04 million stake. Q3 results showed a net loss of $106.4 million on $0.89 million in revenue. About 69% of shares are now held by institutions and hedge funds.
7 December 2025
··
INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Inovio Pharmaceuticals closed at $2.07 on December 5, up 2.5% for the day and nearly 20% over the past 10 sessions, with volume near 1 million shares. The stock recently crossed its 200-day moving average, while short interest remains high at 34% of daily volume. Wall Street’s average 12-month price target is $9, despite continued losses and minimal revenue.
7 December 2025
···
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Aditxt (NASDAQ: ADTX) traded around $3 per share midday December 5, 2025, with a market cap near $1.7 million and only 559,000 shares outstanding. The company reported $2,770 in revenue and a $37.6 million net loss for the first nine months of 2025, holding $163,041 in cash as of September 30. ADTX faces ongoing Nasdaq delisting risk after a 1-for-113 reverse split. Trading remains volatile with heavy short interest.
5 December 2025
··
SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc (SPRC) Stock on December 5, 2025: Price Action, Quantum Data Deal, GERD Device Pivot and 2030 Forecast

SciSparc Ltd. shares closed at $1.80 on December 5, 2025, after surging on volume above 10 million, following news of a quantum bio-data analytics deal via its NeuroThera subsidiary. The stock remains down over 70% in the past year and trades more than 95% below its 52-week high of $37.59, leaving the company with a market cap near $5.8 million.
5 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical shares jumped 83% to $3.69 on December 4 after new data on its Emperor Total Artificial Heart was presented at ISMCS 2025 in Vienna. Trading volume soared to nearly 39 million shares. The company’s market cap reached $272 million, but the stock remains down over 70% from its October high of $13.68. After-hours trading showed some profit-taking, with prices around $3.30–$3.40.
5 December 2025
···
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics shares surged 8.5% to $56 on December 3, landing mid-range between their 52-week low of $30 and high of $78. The company reported a $106 million Q3 net loss on $0.9 million in revenue but holds $1.9 billion in cash. Takeover rumors persist, though no formal bids have emerged. Wall Street price targets range widely, with consensus in the high-$60s to mid-$70s.
4 December 2025
·
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics shares surged over 300% to nearly $30 after Phase 3 data showed its Deramiocel cell therapy slowed upper-limb decline by 54% and preserved 91% of heart function in Duchenne muscular dystrophy patients. The HOPE-3 trial enrolled 106 mostly non-ambulatory boys and young men. Trading was volatile, with the stock flagged as “extremely overbought.”
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics shares jumped over 380% Wednesday after reporting positive Phase 3 HOPE-3 trial results for deramiocel in Duchenne muscular dystrophy. The stock opened near $30, up from $6.36, hitting intraday highs around $40 on volume over 40 million shares. The FDA previously rejected deramiocel but will review new data for possible approval in 2026. Capricor ended Q3 with $98.6 million in cash.
3 December 2025
···
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics shares surged over 500% on December 3, 2025, after its Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met all primary and key secondary endpoints. The trial showed a 54% slowing of upper limb decline and 91% preservation of heart function versus placebo. Capricor plans to resubmit its BLA to the FDA, addressing a previous Complete Response Letter. The stock traded around $39–40 intraday, up from $6.36.
3 December 2025
···
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd shares surged 130% on December 2 after announcing a manufacturing upscaling milestone for its PL‑14 nasal allergy blocker. The stock closed at $7.33, up from $3.16, with trading volume near 150 million shares. The Israeli biotech, which has no approved products or revenue, now trades around $6 pre-market. Polyrizon develops intranasal hydrogel sprays and remains in the pre-commercial stage.
3 December 2025
··
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen shares traded at $338.67 on December 2, 2025, up 0.35% and near 52-week highs after strong Q3 results and a raised 2025 outlook. Several institutional investors disclosed reduced AMGN holdings in Q2 filings. Technical analysts flagged a short-term bullish setup. The company’s obesity and cardiovascular drugs remain key pipeline drivers.
2 December 2025
···
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio shares surged up to 13% on November 28 after reporting Q3 revenue of $32.1 million, up from $6.1 million a year earlier, driven by Anktiva sales. The company posted a Q3 net loss of $67.3 million and a nine-month cash outflow of $234.6 million. Anktiva is FDA-approved for certain bladder cancer patients in the U.S. and recently gained UK approval. Shares remain down mid-teens for the year.
29 November 2025
···
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX shares closed at HK$414.80 on November 27, 2025, up 0.4% amid derivatives expiries and anticipation of Hang Seng Biotech Index futures. The stock traded between HK$410.00 and HK$416.00 on about 1.8 million shares. HKEX is up roughly 40–45% year-on-year, trading in the upper half of its 52-week range. The Hang Seng Index ended at 25,942.5, up 0.06%.
27 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical data showing its lead drug Telomir-1 killed HL60 leukemia cells in vitro. Director Dr. Craig Eagle resigned from the board, effective November 14, with no dispute cited. TELO stock jumped 8% pre-market but recently traded at $1.39, down 3% from the prior close. Shares remain down about two-thirds year-to-date.
21 November 2025
··
1 … 8 9 10 11 12 … 16

Stock Market Today

  • QuidelOrtho (QDEL) Shares Slide 23% in a Month Amid Valuation Debate
    April 8, 2026, 9:37 PM EDT. QuidelOrtho (QDEL) shares slipped 22.86% over the past month to $15.32, despite a 2.27% gain on the latest trading day. The stock's 1-year total shareholder return tallies 46.90%, showing past momentum is fading. Analysts flag a sharp valuation gap: market price trails the $34.67 fair value estimate by over 80%, spotlighting risks in execution and reimbursement trends. Expansion into global markets like Latin America and Asia Pacific offers growth potential, underpinned by demand for early detection and immunoassay technologies. But COVID testing normalization and product discontinuations weigh on revenue diversity and margins. Investors should weigh these mixed signals carefully and consider broadening healthcare AI exposure rather than concentrating on one stock story.

Latest article

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

Alphabet Stock (GOOG, GOOGL) Faces Split Fund Bets Ahead of Earnings After Fresh 13F Reports

8 April 2026
Zevenbergen Capital increased its Alphabet Class A share holdings by 27.4% in Q4, while Lombard Odier and Empirical Wealth Management reduced their Class C positions, according to April 7 filings. Alphabet will report first-quarter results on April 29. GOOG and GOOGL traded near $304 before Wednesday’s U.S. open. The filings reflect holdings as of December 31 and may not show current positions.
Go toTop